RxDoctor Payments Data

Zipora Martin-Brown

Family · Jackson, MSNPI 1912471939

Payments from drug & device makers

$666in general payments, 2019–2025

Across 27 payments — averaging $24.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$250
  • Lilly USA, LLC$119
  • Boehringer Ingelheim$90
  • GSK$56
  • Vanda Pharmaceuticals Inc.$31
  • Otsuka America Pharmaceutical, Inc.$23
  • plus $97 from 6 others

What the payments were for

  • Food & beverage$666100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$666 in reported general payments places this provider in the 60th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$5,774
Medicare patients
51
Services billed
105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin75$112,945
TrulicityDulaglutide65$86,084
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$80,393
TradjentaLinagliptin54$61,629
OzempicSemaglutide28$42,916
EliquisApixaban45$42,113
MounjaroTirzepatide21$32,124
FarxigaDapagliflozin Propanediol22$31,741
Tresiba Flextouch U-100Insulin Degludec33$27,159
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$18,480
LinzessLinaclotide20$17,844
MyrbetriqMirabegron12$15,376
XareltoRivaroxaban14$12,974
Tresiba Flextouch U-200Insulin Degludec18$11,449
SymbicortBudesonide/Formoterol Fumarate20$8,041

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$90$174,574129 claims
Lilly USA, LLCTrulicity, Mounjaro$119$118,20786 claims
GSKTrelegy Ellipta$56$80,39361 claims
Novo NordiskOzempic$250$42,91628 claims
Sanofi-aventis U.S. LLCLantus$13$2,79316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,007 family providers in Mississippi.

Other family in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →